Literature DB >> 8421164

Relationship of hepatitis B virus infection to human immunodeficiency virus type 1 infection.

S J Twu1, R Detels, K Nelson, B R Visscher, R Kaslow, J Palenicek, J Phair.   

Abstract

The Multicenter AIDS Cohort Study (MACS) was designed to study the natural history of human immunodeficiency virus type 1 (HIV-1) infection, including the relationship between hepatitis B virus (HBV) and HIV-1 infection. In total, 4954 homosexual men were recruited from April 1984 through March 1985 and have been followed up thereafter every 6 months. Hepatitis B surface antigen and hepatitis B core antibody were tested for at the first visit by RIA or EIA; HIV-1 antibody testing was done at each visit by ELISA and confirmed by Western blot assay. The role of HBV infection in HIV-1 seroconversion was studied by stratification for sexual behavior and disease visit by visit. The adjusted risk ratio was 2.02 for hepatitis B surface antigen carriers and 2.14 for hepatitis-immune cases compared with hepatitis B-susceptible subjects. Similar results were obtained using a logistic regression model. After taking into account changes in sexual behavior and disease over time, the authors conclude that past HBV infection remains suspect as a cofactor or as a surrogate for other factors associated with HIV-1 seroconversion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8421164     DOI: 10.1093/infdis/167.2.299

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Seroconversion to HBV associated with seroconversion to HIV in a cohort of intravenous drug misusers in Turin, Italy.

Authors:  A Sinicco; R Fora; M Sciandra; R Raiteri
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

2.  Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

Authors:  Eneida A Santos; Michel V F Sucupira; Juçara Arabe; Selma A Gomes
Journal:  BMC Infect Dis       Date:  2004-08-31       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.